A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitis - PubMed
3 hours ago
- #probiotics
- #bile acids
- #intestinal fibrosis
- Intestinal fibrosis is a severe complication of Crohn's disease with suboptimal therapy.
- Probiotics are used for intestinal inflammation, but guidelines mostly do not recommend them, except for an 8-strain formula for ulcerative colitis.
- A 9-strain probiotic with Lactobacillus rhamnosus and paracasei was tested in a mouse model of intestinal inflammation and fibrosis.
- The 9-strain probiotic showed similar effects to the 8-strain in acute colitis but was superior in chronic colitis, reducing inflammation and fibrosis.
- The 9-strain probiotic remodeled microbiota and bile acids, enriching GPBAR1 agonists like 3-oxo-DCA, which attenuates fibroblast activation.
- Gpbar1-deficient mice did not benefit from the 9-strain probiotic, confirming the role of the bile acid-GPBAR1 pathway.
- The study highlights the importance of microbial metabolites in probiotic efficacy and supports targeting host-microbiota interactions via bile acid signaling.